Livmoniplimab is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Livmoniplimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Livmoniplimab (ABBV-151) is under development for the treatment of colorectal cancer, pancreatic adenocarcinoma, urothelial cancer, metastatic hepatocellular carcinoma (HCC), advanced or metastatic solid tumors, head and neck squamous cell carcinoma (HNSCC), oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer and laryngeal cancer, non-small cell lung cancer, colorectal cancer. The therapeutic candidate is developed based on the SIMPLE Antibody platform technology. It is administered as a liquid for intravenous infusion. It acts by targeting cell surface membrane protein GARP.
It was also under development for the treatment of graft versus host disease, triple-negative breast cancer (TNBC).
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of Livmoniplimab’s drug-specific PTSR and LoA scores, buy the report here.